Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fatty Acid Type Clear all
Completed No phase listed Observational Accepts healthy volunteers

Production of Free Fatty Acids From Blood Triglycerides

NCT00911482
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Dyslipidemias
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Fish Oil and Aspirin With Type 2 Diabetes

NCT01181882
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Fish Oil and Aspirin
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety

NCT03689738
View directory record Official record
Conditions
Insulin Sensitivity, Lipid Metabolism, Resistant Starch, Potato
Interventions
Potato (Resistant Starch), CHO-matched (Low-fiber, RS-free)
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 15, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 15, 2026, 2:10 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Regional Fatty Acid Metabolism in Humans

NCT00068887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 15, 2026, 2:10 AM EDT
Recruiting Not applicable Interventional

Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06337812
View directory record Official record
Conditions
Type2diabetes, Heart Failure With Preserved Ejection Fraction
Interventions
Potato Starch
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

NCT00577590
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Metformin, Rosiglitazone, Lovaza
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Nutritional Intervention to Prevent Diabetes

NCT00333554
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DHA Treatment, Placebo for DHA
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Up to 5 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 15, 2026, 2:10 AM EDT
Completed No phase listed Observational

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

NCT00256633
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carnitine and Liver Mitochondria Fatty Acid Processing

NCT03193125
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Obesity
Interventions
L-Carnitine, Placebo
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

NCT01580813
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Acipimox, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise

NCT00795860
View directory record Official record
Conditions
Insulin Resistance and Type 2 Diabetes
Interventions
Weight loss - diet only, Weight loss plus exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus

NCT00308373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin vs Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2010 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency

NCT01371825
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions
Sebelipase alfa (SBC-102)
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes.

NCT00724087
View directory record Official record
Conditions
Sleep, Sleep Deprivation, Insulin Resistance, Type 2 Diabetes
Interventions
5.5-hour bedtime, 8.5-hour bedtime
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 15, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

NCT05499702
View directory record Official record
Conditions
Type2diabetes
Interventions
Caloric Restriction, Hyperglycemic clamp
Behavioral · Drug
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 15, 2026, 2:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.

NCT00720889
View directory record Official record
Conditions
Sleep, Insulin Resistance, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

NCT01633177
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
22,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

NCT02652715
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, B Lymphoblastic Leukemia/Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Hepatosplenic T-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mycosis Fungoides, Nasal Type Extranodal NK/T-Cell Lymphoma, Nodal Marginal Zone Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Effusion Lymphoma, Sezary Syndrome, Splenic Marginal Zone Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, T Lymphoblastic Leukemia/Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Salvia hispanica Seed
Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

Cord Blood Plus Vitamin D and Omega 3s in T1D

NCT00873925
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Autologous UCB, Omega 3 FA, Vitamin D
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes

NCT00738023
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Rosiglitazone, Normal saline 0.9%, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 15, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 15, 2026, 2:10 AM EDT